• 1
    Easton DF, Deffenbaugh AM, Pruss D et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007: 81: 873883.
  • 2
    Walsh ER, Pisitkun P, Voynova E et al. Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity. Proc Natl Acad Sci U S A 2012: 109: 1627616281.
  • 3
    Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K. Genetics, genomics and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 2011: 61: 327359.
  • 4
    Stuenkel AJ, Tandy SL, Siegfried JD. Estimated variant rate for a next-generation sequencing panel of 13 genes associated with hereditary colon cancer. San Francisco, CA: American Society of Human Genetics Annual Meeting, 2012.
  • 5
    Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet 2009: 85: 142154.
  • 6
    Saam J, Burbidge L, Bowles K et al. Decline in rate of BRCA1/2 variants of uncertain significance: 2002–2008. 27th Annual Education Conference of the National Society of Genetic Counselors. Los Angeles, 2008.
  • 7
    Domchek S, Weber BL. Genetic variants of uncertain significance: flies in the ointment. J Clin Oncol 2008: 26: 1617.
  • 8
    Ardern-Jones A, Kenen R, Lynch E, Doherty R, Eeles R. Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives. Hered Cancer Clin Pract 2010: 8: 1.
  • 9
    Brierley KL, Campfield D, Ducaine W et al. Errors in delivery of cancer genetics services: implications for practice. Conn Med 2010: 74: 413423.
  • 10
    Brierley KL, Blouch E, Cogswell W et al. Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. Cancer J 2012: 18: 303309.
  • 11
    Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc 2010: 85: 11111120.
  • 12
    NCCN. NCCN clinical practice guidelines in oncology V.1.2012: Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines, 2012.
  • 13
    Riley BD, Culver JO, Skrzynia C et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012: 21: 151161.
  • 14
    Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989: 81: 18791886.
  • 15
    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 1994: 73: 643651.
  • 16
    Vos J, Otten W, van Asperen C, Jansen A, Menko F, Tibben A. The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psychooncology 2008: 17: 822830.
  • 17
    Vos J, Oosterwijk JC, Gomez-Garcia E et al. Perceiving cancer-risks and heredity-likelihood in genetic-counseling: how counselees recall and interpret BRCA 1/2-test results. Clin Genet 2011: 79: 207218.
  • 18
    van Dijk S, van Asperen CJ, Jacobi CE et al. Variants of uncertain clinical significance as a result of BRCA1/2 testing: impact of an ambiguous breast cancer risk message. Genet Test 2004: 8: 235239.
  • 19
    MacDonald DJ, Blazer KR, Weitzel JN. Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Canc Netw 2010: 8: 615624.
  • 20
    Blazer KR, MacDonald DJ, Culver JO et al. Personalized cancer genetics training for personalized medicine: improving community-based healthcare through a genetically literate workforce. Genet Med 2011: 13: 832840.
  • 21
    Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003: 138: 13231329.
  • 22
    Schwartz MD, Lerman C, Brogan B et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004: 22: 18231829.
  • 23
    Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 2009: 101: 10581065.
  • 24
    Hemminki K, Vaittinen P. Familial risks in second primary breast cancer based on a family cancer database. Eur J Cancer 1999: 35: 455458.
  • 25
    Hemminki K, Ji J, Forsti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res 2007: 67: 868870.
  • 26
    Harris RE, Lynch HT, Guirgis HA. Familial breast cancer: risk to the contralateral breast. J Natl Cancer Inst 1978: 60: 955960.
  • 27
    Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998: 105: 493499.
  • 28
    Kauff ND, Mitra N, Robson ME et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 2005: 97: 13821384.
  • 29
    Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998: 90: 13711388.
  • 30
    Saslow D, Boetes C, Burke W et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007: 57: 7589.
  • 31
    Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004: 23: 11111130.
  • 32
    Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004: 91: 15801590.
  • 33
    MacDonald DJ, Choi J, Ferrell B et al. Concerns of women presenting to a comprehensive cancer center for genetic cancer risk assessment. J Med Genet 2002: 39: 526530.
  • 34
    NCCN. NCCN clinical practice guidelines in oncology V.2.2012: Breast Cancer. NCCN Clinical Practice Guidelines, 2012.
  • 35
    Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M. Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol 2007: 14: 24252427.
  • 36
    National Institutes of Health (NIH). NIH Consensus Conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995: 273: 491497.
  • 37
    SGO. Society of Gynecologic Oncologists Clinical Practice Committee Statement on prophylactic salpingo-oophorectomy. Gynecol Oncol 2005: 98: 179181.
  • 38
    ACOG. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol 2008: 111: 231241.
  • 39
    NCCN. NCCN Guidelines Breast Cancer Risk Reduction V.1.2012. NCCN Guidelines for Detection, Prevention, & Risk Reduction, 2012.
  • 40
    Bilimoria MM, Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin 1995: 45: 263278.
  • 41
    Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med 2011: 13 (12): 9981005.
  • 42
    Schwartz MD, Kaufman E, Peshkin BN et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 2003: 21: 40344041.
  • 43
    Uyei A, Peterson SK, Erlichman J et al. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 2006: 107: 27452751.
  • 44
    Morgan D, Sylvester H, Lucas FL, Miesfeldt S. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer 2009: 8: 277287.
  • 45
    Schwartz MD, Isaacs C, Graves KD et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 2012: 118: 510517.
  • 46
    Julian-Reynier CM, Bouchard LJ, Evans DG et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another. Cancer 2001: 92: 959968.
  • 47
    Hallowell N, Foster C, Ardern-Jones A, Eeles R, Murday V, Watson M. Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching. Genet Test 2002: 6: 7987.
  • 48
    van Dijk S, Otten W, Tollenaar R, van Asperen C, Tibben A. Putting it all behind: long-term psychological impact of an inconclusive DNA test result for breast cancer. Genet Med 2008: 10: 745750.
  • 49
    Pritchard CC, Smith C, Salipante SJ et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012: 14: 357366.